{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:47:31Z","timestamp":1790765251279,"version":"4.1.0"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Linezolid is a second-line medication used to treat tuberculosis that has become resistant to multiple drugs. Linezolid has been shown to be effective in treating drug-resistant TB. However, long-term therapy is hampered by the related side effects, such as ocular and peripheral neuropathy. We recently encountered a 32-year-old male undergoing linezolid therapy for 12 months for multidrug-resistant tuberculosis who presented with progressive painless visual impairment and peripheral neuropathy symptoms in lower limbs as well as ataxic gait. Nerve conduction study findings of length-dependent axonal sensory polyneuropathy with bilateral optic neuropathy evident on fundoscopy suggested a case of toxic neuropathy. Following the termination of linezolid, follow-up visits revealed an improvement in visual symptoms. While there has been no discernible improvement or deterioration of peripheral neuropathy. In a developing country like Pakistan, where the rising number of cases of multidrug-resistant tuberculosis and its management is a major problem, physicians should be made aware of linezolid induced neuropathy so that close follow-up sessions for patients on long-term linezolid therapy can be arranged to avoid serious neurological consequences.<\/jats:p>","DOI":"10.3389\/fneur.2022.908584","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T08:58:24Z","timestamp":1656061104000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["A Case Report and Literature Review of the Outcome of Linezolid-Induced Optic and Peripheral Neuropathy in Patients With Multidrug-Resistant Pulmonary TB"],"prefix":"10.3389","volume":"13","author":[{"given":"Safia","family":"Bano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Nawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahsan","family":"Numan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Aarish","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Bilal Ahmad","family":"Shafique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"key":"B1","unstructured":"Global Tuberculosis Report.2018"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1602352","DOI":"10.1183\/13993003.02352-2016","article-title":"Target regimen profiles for treatment of tuberculosis: a WHO document","volume":"49","author":"Lienhardt","year":"2017","journal-title":"Eur Respir J"},{"key":"B3","unstructured":"Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.4103\/0301-4738.118451","article-title":"Linezolid-induced optic neuropathy","volume":"62","author":"Karuppannasamy","year":"2014","journal-title":"Indian J Ophthalmol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1592\/phco.27.8.1189","article-title":"Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome","volume":"27","author":"Narita","year":"2007","journal-title":"Pharmacotherapy."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3201\/eid2608.191499","article-title":"Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis, France","volume":"26","author":"Jaspard","year":"2020","journal-title":"Emerg Infect Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12941-016-0156-y","article-title":"Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis","volume":"15","author":"Agyeman","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob."},{"key":"B8","unstructured":"AljebreenMA\n            AlotaibiAK\n            AlrobaianM\n          PubMed Central (PMC)2021"},{"key":"B9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.sjopt.2018.10.010","article-title":"Linezolid induced optic neuropathy in a child treated for extensively drug resistant tuberculosis: a case report and review of literature","volume":"33","author":"Agashe","year":"2019","journal-title":"Saudi J Ophthalmol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.2169\/internalmedicine.1344-18","article-title":"Is severe and long-lasting linezolid-induced optic neuropathy reversible?","volume":"57","author":"Lee","year":"2018","journal-title":"Intern Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.24911\/ejmcr\/1\/28","article-title":"Linezolid induced optic neuropathy, a serious yet reversible adverse effect: a case report","volume":"1","author":"Shah","year":"2017","journal-title":"Eur J Med Case Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1186\/s12879-017-2499-1","article-title":"Peripheral neuropathy in a diabetic child treated with linezolid for multidrug-resistant tuberculosis: a case report and review of the literature","volume":"17","author":"Swaminathan","year":"2017","journal-title":"BMC Infect Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S1473-3099(12)70272-4","article-title":"Linezolid for multidrug-resistant tuberculosis\u2013Authors' reply","volume":"13","author":"Chang","year":"2013","journal-title":"Lancet Infect Dis."},{"key":"B14","volume-title":"Saunders Handbook of Veterinary Drugs-e-Book: Small and Large Animal","author":"Papich","year":"2015"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur Respir J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3978\/j.issn.2072-1439.2015.03.10","article-title":"Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis","volume":"7","author":"Zhang","year":"2015","journal-title":"J Thorac Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1086\/501356","article-title":"Linezolid-induced inhibition of mitochondrial protein synthesis","volume":"42","author":"De Vriese","year":"2006","journal-title":"Clin Infect Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/bjo.2006.102541","article-title":"Linezolid-induced optic neuropathy: a mitochondrial disorder?","volume":"91","author":"Javaheri","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"B19","first-page":"1136","article-title":"Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid in healthy human subjects","volume":"29","author":"Slatter","year":"2001","journal-title":"Drug Metab Dispos."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.908584\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T08:58:30Z","timestamp":1656061110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.908584\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":19,"alternative-id":["10.3389\/fneur.2022.908584"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.908584","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,24]]},"article-number":"908584"}}